Switch theme
Sign up to access all valuation multiples
GlaxoSmithKline Pakistan Ltd is engaged in research, development, and manufacturing pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from Pharmaceuticals segment.
2001
1.7K+
LTM Revenue n/a
LTM EBITDA n/a
$510M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GlaxoSmithKline Pakistan has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, GlaxoSmithKline Pakistan achieved revenue of $218M and an EBITDA of $41.6M.
GlaxoSmithKline Pakistan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GlaxoSmithKline Pakistan valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $177M | $218M | XXX | XXX | XXX |
| Gross Profit | $26.0M | $12.5M | XXX | XXX | XXX |
| Gross Margin | 15% | 6% | XXX | XXX | XXX |
| EBITDA | $11.1M | $41.6M | XXX | XXX | XXX |
| EBITDA Margin | 6% | 19% | XXX | XXX | XXX |
| Net Profit | $8.8M | $1.9M | XXX | XXX | XXX |
| Net Margin | 5% | 1% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, GlaxoSmithKline Pakistan's stock price is PKR 468 (or $2).
GlaxoSmithKline Pakistan has current market cap of PKR 149B (or $533M), and EV of PKR 143B (or $510M).
See GlaxoSmithKline Pakistan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $510M | $533M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, GlaxoSmithKline Pakistan has market cap of $533M and EV of $510M.
GlaxoSmithKline Pakistan's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate GlaxoSmithKline Pakistan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for GlaxoSmithKline Pakistan and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $510M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 12.3x | XXX | XXX | XXX |
| P/E | 22.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 62.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGlaxoSmithKline Pakistan's NTM/LTM revenue growth is n/a
GlaxoSmithKline Pakistan's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $11K for the same period.
Over next 12 months, GlaxoSmithKline Pakistan's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate GlaxoSmithKline Pakistan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for GlaxoSmithKline Pakistan and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 273% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $11K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 9% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GlaxoSmithKline Pakistan acquired XXX companies to date.
Last acquisition by GlaxoSmithKline Pakistan was XXXXXXXX, XXXXX XXXXX XXXXXX . GlaxoSmithKline Pakistan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was GlaxoSmithKline Pakistan founded? | GlaxoSmithKline Pakistan was founded in 2001. |
| Where is GlaxoSmithKline Pakistan headquartered? | GlaxoSmithKline Pakistan is headquartered in Pakistan. |
| How many employees does GlaxoSmithKline Pakistan have? | As of today, GlaxoSmithKline Pakistan has 1.7K+ employees. |
| Is GlaxoSmithKline Pakistan publicy listed? | Yes, GlaxoSmithKline Pakistan is a public company listed on KAR. |
| What is the stock symbol of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan trades under GLAXO ticker. |
| When did GlaxoSmithKline Pakistan go public? | GlaxoSmithKline Pakistan went public in 1953. |
| Who are competitors of GlaxoSmithKline Pakistan? | Similar companies to GlaxoSmithKline Pakistan include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan's current market cap is $533M |
| What is the current revenue growth of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan revenue growth between 2023 and 2024 was 23%. |
| Is GlaxoSmithKline Pakistan profitable? | Yes, GlaxoSmithKline Pakistan is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
